-
公开(公告)号：US20190015437A1
公开(公告)日：2019-01-17
申请号：US15918477
申请日：2018-03-12
发明人： Uli Christian Broedl , Odd-Erik Johansen , Gabriel Woojai Kim , Eric Williams Mayoux , Afshin Salsali , Nima Soleymanlou , Maximilian von Eynatten , Hans-Juergen Woerle , David Z.I. Cherney , Bruce A. Perkins , Andreas Daiber , Thomas Muenzel
IPC分类号： A61K31/7048 , A61K31/522 , A61K31/155 , A61K31/7034 , A61K45/06 , A61K9/28 , A61K9/20
摘要： The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
-
公开(公告)号：US09949997B2
公开(公告)日：2018-04-24
申请号：US14918713
申请日：2015-10-21
发明人： Uli Christian Broedl , Odd-Erik Johansen , Gabriel Woojai Kim , Eric Williams Mayoux , Afshin Salsali , Nima Soleymanlou , Maximilian von Eynatten , Hans-Juergen Woerle , David Z. I. Cherney , Bruce A. Perkins , Andreas Daiber , Thomas Muenzel
IPC分类号： A61K31/7048 , A61K31/155 , A61K31/522 , A61K31/7034 , A61K45/06 , A61K9/20 , A61K9/28
CPC分类号： A61K31/7048 , A61K9/2018 , A61K9/2866 , A61K31/155 , A61K31/522 , A61K31/7034 , A61K45/06 , A61K2300/00
摘要： The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
-
公开(公告)号：US11833166B2
公开(公告)日：2023-12-05
申请号：US17344003
申请日：2021-06-10
IPC分类号： A61K31/7034 , A61K31/7048 , A61K9/20 , A61K9/28
CPC分类号： A61K31/7048 , A61K9/2018 , A61K9/2866 , A61K31/7034
摘要： The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).
-
4.发明授权Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome 有权在足细胞相关疾病和/或肾病综合征中使用DPP-4抑制剂公开(公告)号：US09526730B2
公开(公告)日：2016-12-27
申请号：US14928048
申请日：2015-10-30
IPC分类号： A61K38/13 , A61K31/522 , C07D473/06 , A61K45/06
CPC分类号： A61K31/522 , A61K31/155 , A61K31/18 , A61K38/28 , A61K45/06 , C07D473/06
摘要： The present invention relates to methods for treating and/or preventing podocytes related disorders and/or nephrotic syndrome comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and/or nephrotic syndrome.
摘要翻译： 本发明涉及用于治疗和/或预防足细胞相关疾病和/或肾病综合征的方法，包括施用有效量的某些DPP-4抑制剂，以及使用某种DPP-4抑制剂治疗 和/或预防患有足细胞相关疾病和/或肾病综合征或处于足细胞相关疾病和/或肾病综合征风险的患者中的代谢疾病。
-
公开(公告)号：US11918596B2
公开(公告)日：2024-03-05
申请号：US17381488
申请日：2021-07-21
发明人： Uli Christian Broedl , Odd-Erik Johansen , Gabriel Woojai Kim , Eric Williams Mayoux , Afshin Salsali , Nima Soleymanlou , Maximilian von Eynatten , Hans-Juergen Woerle , David Z. I. Cherney , Bruce A. Perkins , Andreas Daiber , Thomas Muenzel
IPC分类号： A61K31/7048 , A61K9/20 , A61K9/28 , A61K31/155 , A61K31/522 , A61K31/7034 , A61K45/06
CPC分类号： A61K31/7048 , A61K9/2018 , A61K9/2866 , A61K31/155 , A61K31/522 , A61K31/7034 , A61K45/06 , A61K31/7048 , A61K2300/00 , A61K31/155 , A61K2300/00 , A61K31/522 , A61K2300/00
摘要： The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
-
公开(公告)号：US10258637B2
公开(公告)日：2019-04-16
申请号：US15918401
申请日：2018-03-12
IPC分类号： A61K31/7034 , A61K31/7048 , A61K9/20 , A61K9/28
摘要： The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).
-
公开(公告)号：US09949998B2
公开(公告)日：2018-04-24
申请号：US14918727
申请日：2015-10-21
IPC分类号： A61K31/7034 , A61K31/7048 , A61K9/20 , A61K9/28
CPC分类号： A61K31/7048 , A61K9/2018 , A61K9/2866 , A61K31/7034
摘要： The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).
-
公开(公告)号：US11813275B2
公开(公告)日：2023-11-14
申请号：US17381498
申请日：2021-07-21
发明人： Uli Christian Broedl , Odd-Erik Johansen , Gabriel Woojai Kim , Eric Williams Mayoux , Afshin Salsali , Nima Soleymanlou , Maximilian von Eynatten , Hans-Juergen Woerle , David Z.I. Cherney , Bruce A. Perkins , Andreas Daiber , Thomas Muenzel
IPC分类号： A61K31/7048 , A61K9/20 , A61K9/28
CPC分类号： A61K31/7048 , A61K9/2018 , A61K9/2866
摘要： The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
-
公开(公告)号：US11666590B2
公开(公告)日：2023-06-06
申请号：US17094037
申请日：2020-11-10
发明人： Uli Christian Broedl , Odd-Erik Johansen , Eric Williams Mayoux , Nima Soleymanlou , Maximilian von Eynatten , Hans-Juergen Woerle , David Z.I. Cherney , Bruce A. Perkins
IPC分类号： A61K31/7048 , A61K45/06 , A61K38/28 , A61K9/20 , A61K9/28 , A61K31/155 , A61K31/522
CPC分类号： A61K31/7048 , A61K9/2018 , A61K9/2866 , A61K31/155 , A61K31/522 , A61K38/28 , A61K45/06 , A61K31/155 , A61K2300/00 , A61K31/7048 , A61K2300/00 , A61K38/28 , A61K2300/00 , A61K31/522 , A61K2300/00
摘要： The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.
-
公开(公告)号：US11090323B2
公开(公告)日：2021-08-17
申请号：US16288192
申请日：2019-02-28
IPC分类号： A61K31/7048 , A61K31/7034 , A61K9/20 , A61K9/28
摘要： The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.024 秒)
